260 related articles for article (PubMed ID: 22554140)
1. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
Copher R; Cerulli A; Watkins A; Laura Monsalvo M
J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
[TBL] [Abstract][Full Text] [Related]
3. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
4. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
6. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Nov; 9(6):377-87. PubMed ID: 21888449
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
9. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
[TBL] [Abstract][Full Text] [Related]
10. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
12. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.
Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G
BMC Pulm Med; 2012 Dec; 12():75. PubMed ID: 23231890
[TBL] [Abstract][Full Text] [Related]
13. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
14. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
15. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
16. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia.
Heresi GA; Platt DM; Wang W; Divers CH; Joish VN; Teal SA; Yu JS
BMC Pulm Med; 2017 Apr; 17(1):58. PubMed ID: 28399914
[TBL] [Abstract][Full Text] [Related]
17. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Ivanova JI; Birnbaum HG; Schiller M; Kantor E; Johnstone BM; Swindle RW
Spine J; 2011 Jul; 11(7):622-32. PubMed ID: 21601533
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
AbuDagga A; Sun SX; Tan H; Solem CT
J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
20. Baseline history of patients using selexipag for pulmonary arterial hypertension.
Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
